Have a feature idea you'd love to see implemented? Let us know!

IRWD Ironwood Pharmaceuticals Inc

Price (delayed)

$4.3

Market cap

$686.88M

P/E Ratio

71.67

Dividend/share

N/A

EPS

$0.06

Enterprise value

$1.22B

Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the ...

Highlights
The EPS has surged by 101% year-on-year and by 101% since the previous quarter
The net income has soared by 101% YoY and by 101% from the previous quarter
IRWD's revenue is down by 6% YoY and by 3.1% QoQ
Ironwood Pharmaceuticals's gross profit has decreased by 6% YoY and by 3.1% QoQ

Key stats

What are the main financial stats of IRWD
Market
Shares outstanding
159.74M
Market cap
$686.88M
Enterprise value
$1.22B
Valuations
Price to book (P/B)
N/A
Price to sales (P/S)
1.71
EV/EBIT
10.09
EV/EBITDA
9.92
EV/Sales
3.05
Earnings
Revenue
$400.57M
EBIT
$121.12M
EBITDA
$123.16M
Free cash flow
$146.36M
Per share
EPS
$0.06
Free cash flow per share
$0.92
Book value per share
-$2.02
Revenue per share
$2.52
TBVPS
$2.47
Balance sheet
Total assets
$395.62M
Total liabilities
$717.35M
Debt
$640.26M
Equity
-$321.73M
Working capital
$132.67M
Liquidity
Debt to equity
-1.99
Current ratio
3.92
Quick ratio
3.6
Net debt/EBITDA
4.34
Margins
EBITDA margin
30.7%
Gross margin
100%
Net margin
2.3%
Operating margin
28.4%
Efficiency
Return on assets
2%
Return on equity
N/A
Return on invested capital
14.6%
Return on capital employed
34.6%
Return on sales
30.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IRWD stock price

How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
1.65%
1 week
6.97%
1 month
-13.31%
1 year
-55.44%
YTD
-62.41%
QTD
4.37%

Financial performance

How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$400.57M
Gross profit
$400.57M
Operating income
$113.61M
Net income
$9.21M
Gross margin
100%
Net margin
2.3%
IRWD's operating margin has surged by 114% year-on-year and by 112% since the previous quarter
The operating income has soared by 113% YoY and by 111% from the previous quarter
IRWD's net margin has surged by 101% year-on-year and by 101% since the previous quarter
The net income has soared by 101% YoY and by 101% from the previous quarter

Growth

What is Ironwood Pharmaceuticals's growth rate over time

Valuation

What is Ironwood Pharmaceuticals stock price valuation
P/E
71.67
P/B
N/A
P/S
1.71
EV/EBIT
10.09
EV/EBITDA
9.92
EV/Sales
3.05
The EPS has surged by 101% year-on-year and by 101% since the previous quarter
The company's equity rose by 7% YoY and by 2.7% QoQ
IRWD's P/S is 58% below its 5-year quarterly average of 4.1 and 50% below its last 4 quarters average of 3.4
IRWD's revenue is down by 6% YoY and by 3.1% QoQ

Efficiency

How efficient is Ironwood Pharmaceuticals business performance
Ironwood Pharmaceuticals's ROIC has soared by 115% YoY and by 113% from the previous quarter
The return on sales has surged by 115% year-on-year and by 113% since the previous quarter
Ironwood Pharmaceuticals's return on assets has surged by 102% YoY and by 101% QoQ

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals financials performed over time
The total assets is 45% less than the total liabilities
The total assets has contracted by 34% YoY and by 10% from the previous quarter
IRWD's total liabilities is down by 24% year-on-year and by 7% since the previous quarter
IRWD's debt is down by 22% year-on-year and by 7% since the previous quarter
The company's debt to equity rose by 16% YoY and by 4.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.